Find Clinical Trial

Home » Find Clinical Trials » A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation

← Back

Study Phase	Phase 1

Therapeutic Area	Cancers

Indication	Acute Myeloid Leukemia

Sponsor	Institut de Recherches Internationales Servier

Active substance/ Medical device	AG-120, AG-221

Active Substance Code	AG-120, AG-221

Protocol Code	AG120-221-C-001

EudraCT Code	2015-004290-33

NCT Code	NCT02632708

Documents and links

Results are not yet available.

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.